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Hyponatremia is associated with increased HE occurrence and influences mortality after acute liver dysfunction (7) (8) (9) . Some hypothesize that the osmotic mechanism by which astrocytes regulate brain volume is disturbed in HE and hyponatremia strains this system's functional reserve (2, 10, 11) . Acute reduction in serum osmotically active substances (osmolytes) is a proposed mechanism underlying instances of cerebral edema and neurologic deterioration in metabolic disease states, including dialysis disequilibrium syndrome, diabetic ketoacidosis, hyperosmolar hyperglycemic state, exerciseassociated hyponatremia, and rebound cerebral edema after mannitol therapy (12) (13) (14) (15) (16) (17) (18) . As osmolality is rarely monitored in acute liver disease, it is possible that unrecognized osmolality changes might contribute to cerebral edema and neurologic deterioration in these patients.
Our aim was to investigate if changes in brain volume and neurologic function are associated with acute changes in serum osmolality in patients with severe HE from acute liver failure (ALF) or acute-on-chronic liver failure (ACLF). Secondarily, we examined the effects of renal replacement therapy (RRT) on serum osmolality and brain volume to illustrate an application of attention to osmolality change. We compared RRT administered concurrently with hypertonic saline (HTS)-a therapy used in the ICU to increase serum osmolality-to RRT administered without HTS.
METHODS
We abstracted electronic record data from our neurologic critical care service to retrospectively identify patients greater than or equal to 18 years old admitted to an ICU between July 2012 and June 2017 with ALF or ACLF and severe HE. Given similar phenotypic presentations and our intention to explore pathophysiologic mechanisms, we included patients with either ALF or ACLF (19, 20) . Neurologic critical care consultation is routine for patients with liver failure and West Haven grade 2 (lethargy) or worse HE at our institution (21) . The diagnosis of liver failure was identified from attending intensivist documentation and confirmed according to published definitions (21, 22) . Severe HE was defined as West Haven grade 3 (somnolent) or 4 (coma) as documented by an attending neurologist (21) . Study inclusion required 1) more than or equal to two head CT scans acquired within 48 hours of each other, 2) the first CT scan obtained within 48 hours of admission, 3) availability of serially measured serum osmolality and chemistries, and 4) serially measured Glasgow Coma Scale (GCS) scores, a neurologic examination scale ranging from 3 (deepest coma) to 15 (normal, alert, and oriented). The GCS has good inter-rater reliability and is recommended for use in HE (20, (23) (24) (25) . We excluded patients with craniectomy or drain placement for cerebrospinal fluid (CSF) diversion and acute focal brain lesions (e.g., stroke). Consistent with several members of the U.S. Acute Liver Failure Study Group, we infrequently use invasive intracranial pressure (ICP) monitors to manage HE (26, 27) . In this population, we use hourly neurologic examinations and repeat head CT scans as previously described (28, 29) . Neuroimaging frequency is guided by degree of neurologic impairment, prior imaging, and clinical trajectory. All HE patients in our ICUs receive hourly neurologic assessments, including GCS, performed by trained ICU nurses who electronically record assessments as they are performed (28, 29) .
We collected demographic and clinical data including GCS, measured serum osmolality, and serum chemistry and laboratory data from the electronic medical record for each patient at the time of admission and each CT scan. We collected Richmond Agitation and Sedation Scale scores (RASS, -5 [unarousable] to 0 [alert and calm] to +4 [combative]) as a secondary neurologic examination. We collected doses of analgesics and sedatives administered within both a 2-hour and 6-hour period prior to each neurologic assessment and determined whether sedation increased, decreased, or remained the same between assessments. No patient was exposed to paralytics during these time periods. We calculated model for end-stage liver diseasesodium (MELD-Na) and Acute Physiology Scores (APS) as measures of overall illness severity (30) . Demographic, neurologic examination, laboratory, medication, and neuroimaging data were collected as separate blinded queries.
Intervals for Assessing Volume, Osmolality, and GCS Change
We used the acquisition times of two sequential head CT scans acquired within 48 hours of one another to define intervals over which changes in brain volume and corresponding changes in GCS, individual osmolytes, and total serum osmolality were assessed. Figure 1 illustrates how these assessment intervals were defined. We used patients' initial assessment intervals for our primary analysis but also employed repeated measures statistical techniques to analyze all available assessment intervals. In these patients, we routinely monitor serum osmolality and chemistry panels at least every 6 hours and calculate serum osmolar gaps (31) .
RRT and HTS
We identified the use and administration time of RRT and HTS for each patient. RRT was administered following current methods for liver failure and brain injury (21, 32) .
For all patients with severe HE receiving RRT, our neurocritical care consultants recommend administering concurrent HTS to avoid serum osmolality reductions greater than 10 (grade 4 HE) to 20 (grade 3 HE) mOsm/Kg per day (32, 33) . This includes 3% infusion or 23.4% bolus HTS when RRT is initiated and monitoring osmolality panels to guide HTS-dosing adjustments. We do not use mannitol in liver failure patients, which was confirmed by record review. The use of HTS during Figure 1 . Defining volume change assessment intervals. Volume change assessment intervals were defined for each patient as the time between subsequent CT scans. Cerebrospinal fluid volume was measured on each CT scan, and the change in volume was calculated. The corresponding changes in serum osmolality, serum chemistries, and Glasgow Coma Scale (GCS) neurologic examinations for each assessment interval were determined using values collected nearest the acquisition time of the CT scans. For GCS, we used the hourly neurologic assessment immediately prior to CT scan. Only the initial assessment intervals were used for Spearman correlations and linear and ordinal regression models. All assessment intervals were used for generalized estimating equation models.
RRT is ultimately at the discretion of the primary ICU service. As such, we identified assessment intervals in which patients underwent RRT either with or without concurrent HTS.
Quantification of Volume Change
We measured volumes on 5-mm thick contiguous slice digital imaging and communications in medicine CT scans using semiautomated computer software (Analyze Direct 11.0, Overland Park, KS) and the pixel intensity threshold technique. We previously demonstrated that CSF volume is a reliable biomarker of brain volume change and more indicative of changes than measuring whole brain volume on CT scans (28, 34) .
Statistical Analysis and Approvals
Initial Assessments. We used only initial assessments for calculation of Spearman correlations and both linear and ordinal regression models. We determined correlation coefficients (r s ) for associations between initial changes in CSF volume, osmolality and chemistry variables, and GCS. We sought to determine if acute serum osmolality change is independently associated with CSF volume change (linear regression) and GCS change (ordinal regression) and to quantify these associations with predictive models, examining the impact of multiple covariates. We constructed models stepwise starting with osmolality change and, for GCS models, included sedation change between neurologic assessments. We treated analgesia and sedation categorically as increase, decrease, or no change between assessments because the response to a given dose of sedative varies between patients. Subsequent demographic and clinical variables ( Table 3) were individually assessed for model inclusion. Variables qualified for inclusion by 1) inclusion changed the model's Beta coefficients by greater than the coefficient's se, suggesting modification effect or 2) the variable demonstrated trend towards significance (p < 0.2). For ordinal regression, we confirmed the proportional odds assumption using the test of parallel lines.
Repeated Assessments. We also wanted to determine if associations identified in the initial assessment intervals were present in patients' subsequent assessments. Generalized estimating equations (GEE) allowed us to analyze all available volume change assessments while accounting for some patients having more than one assessment. The variables in the GEE models were those used for the corresponding initial assessment models. We used linear modeling with identity link function for CSF volume change, ordinal modeling with cumulative logit link function for GCS change, and exchangeable correlation matrices.
We compared continuous and ordinal variables between RRT groups using Mann-Whitney U test. We considered twotailed p value of less than or equal to 0.05 significant. Standard statistical software was used (SPSS v.23; IBM, Armonk, NY). The study was approved by our institutional review board with waiver of consent for retrospective study.
RESULTS
There were 140 patients with liver failure and at least grade 2 HE. Reasons for exclusion included: structural brain lesions (30), HE grades less than 3 (36) , and no qualifying neuroimaging (34) . Forty patients (29%) with ALF or ACLF and severe HE were included and contributed 103 assessment intervals (median 2/ patient). Median initial assessment interval duration was 22.8 hours (10.5-31.2 hr) and for all intervals was 13.0 hours (8.6-24.7 hr). Median time between CT scan acquisition and corresponding laboratory measurements was 1.5 hours (0.8-2.6 hr). No patient had invasive ICP monitoring during the study.
Demographic and clinical data for the entire cohort are summarized in Table 1 . Median initial serum osmolality was elevated (310 mOsm/Kg [296-321 mOsm/Kg]), whereas initial serum sodium was normal (137 mEq/L [134-142 mEq/L]). Median magnitude of osmolality change in the initial assessment intervals was 9 mOsm/kg (5-17 mOsm/kg). Reduction in CSF volume commensurate with increased brain volume occurred in 27 initial assessment intervals (68%). We found ALF patients were younger, had higher admission serum sodium, and lower admission serum blood urea nitrogen than ACLF patients but similar disease severity scores and ammonia levels (Supplemental Digital Content 1, http://links.lww.com/ CCM/C988). Supplemental Digital Content 1 (http://links. lww.com/CCM/C988) also summarizes data for all 103 assessment intervals. Table 2 summarizes Spearman correlation coefficients between changes in each osmolyte and changes in CSF volume and GCS score using only the initial volume change assessment from each patient. CSF volume change was associated with osmolality change (r s = 0.70; p = 4 × 10 Table 3 summarizes linear, ordinal, and GEE regression models for CSF volume change and GCS change. In a linear regression model, serum osmolality change was independently associated with CSF volume change (β = 1.54; p = 2.7 × 10 -5 ).
In an ordinal regression model, serum osmolality change (odds ratio, 1.08; p = 1 × 10 -5 ), serum ammonia change (odds ratio, 0.994; p = 0.011), and admission APS (odds ratio, 1.018: p = 0.015) were independently associated with GCS change. Serum osmolality change associations were similar using RASS examinations (Supplemental Digital Content 4, http://links. lww.com/CCM/C991).
The linear GEE model using all 103 assessments also showed an independent association between serum osmolality change and CSF volume change (β = 1.34; p = 3 × 10 -10 ). The ordinal GEE model using all 103 assessments showed an independent association between serum osmolality change and GCS change (odds ratio, 1.07; p = 1 × 10 -8 ).
Of note, ALF versus ACLF did not qualify as a variable for inclusion in any of the above models. Furthermore, separate GEE models demonstrated significant independent associations between CSF volume, GCS, and serum osmolality Twenty-nine patients (73%) had an assessment interval that occurred with RRT. RRT was initiated with concurrent HTS (indicating management with attention to osmolality) in 14 patients (48%) and without HTS in 15 patients (52%). These groups did not differ in MELD-Na, APS, initial GCS score, initial serum ammonia, osmolality, sodium, BUN, glucose, gap osmoles, or method of RRT (intermittent vs continuous). Thirteen patients (33%) died during hospitalization. Although those who died tended to experience lower nadir GCS scores during their initial assessment interval (median 6 [3] [4] [5] [6] [7] vs 7 [4] [5] [6] [7] [8] [9] [10] [11] [12] ; p = 0.08), we did not appreciate a pattern of CSF volume or osmolality change that predicted death.
DISCUSSION
In our cohort of patients with severe HE, decreases in serum osmolality were significantly associated with worsened cerebral edema. Decreasing serum osmolality and increased edema were associated with neurologic worsening. We found evidence that serum osmolality changes affected cerebral edema and neurologic examination in both ALF and ACLF patients, suggesting both groups are subject to the underlying mechanism. Despite bivariate associations between individual osmolytes and CSF volume change, only the aggregate change in osmolality was independently associated with CSF volume change.
Whereas most of our cohort initially had low to normal serum sodium, as expected in liver disease (7-9), the majority nevertheless had elevated serum osmolality. Furthermore, this elevated osmolality included a gap not accounted for by directly measured osmolytes. Gap osmole levels acutely changed in some patients and contributed to total osmolality change. These gap osmoles might represent unrecognized osmotically active molecules that accumulate in liver failure. The contribution of gap osmolytes to acute osmolality change requires that osmolality be directly measured to accurately trend dynamic changes.
Therapeutically induced increases in osmolality, called "osmotherapy," is a widely used treatment for cerebral edema in neurologic injuries (18) . One may suspect that reductions in serum osmolality, potentially accelerated by BUN and gap osmolyte clearance during RRT, could have the inverse effect of worsening cerebral edema. In a trial of 30 patients with acute liver failure, gradual HTS infusion targeting moderate hypernatremia was associated with reduced occurrence of intracranial hypertension compared to controls (33) . Although those authors did not measure osmolality or demonstrate a potential physiologic Determined from 6-hr time period before neurologic assessments, as described in the Methods section. Two-hr time periods yielded similar results. Dash indicates that no median value to report because no medication was used. mechanism, they proposed osmolyte changes as an explanation (33) . Our findings suggest that the gradual infusion of HTS may have buffered changes in nonsodium osmolytes, thereby lessening cerebral edema. RRT is of interest given its widespread use in liver failure and its mechanism in rapidly clearing small molecules from circulation. We found that patients who received RRT with concurrent HTS infusion were less likely to experience a decrease in osmolality or radiographic evidence of brain swelling compared to those who received RRT without HTS. These observations highlight a potential implication of the association between osmolality, neuroimaging findings, and neurologic examination. Even with modern techniques and continuous methods of RRT, critically ill patients-particularly those with brain pathology-may be at risk of neurologic injury or death from cerebral edema associated with RRT (13, 34, 35) . Although some have suggested prophylactic adjustments to dialyzate or infusion of hyperosmolar substances during RRT, most suggestions are based on limited human data and are largely untested (32) . Our data suggest that minimizing decline in serum osmolality during RRT may be associated with favorable clinical endpoints. However, unavailability of data on dialysis settings such as blood flow rate and fluid removal volume is a study limitation. ORs represent the expected odds of GCS improvement (≥ 1 GCS point increase) with a one-unit increase in the predictor variable.
TABLE 1. (Continued). Cohort Demographics and Initial Clinical and Radiographic Characteristics
c Results using the 6-hr time period for analgesia/sedation assessment, as described under the Methods section, are presented. The 2-hr time period yielded similar results. Variables assessed for model inclusion included serum osmolality change, age, sex, acute versus acute-on-chronic liver failure, APS, number of admission systemic inflammatory response syndrome criteria met, model for end-stage liver disease-sodium, renal replacement therapy exposure during assessment interval, mean temperature during assessment interval, temperature change across the assessment interval, serum ammonia change, serum sodium change, serum BUN change, serum glucose change, admission serum ammonia, time delay between serum osmolality measurement and CT scan, and (for GCS models) analgesia/sedation dosage change across the assessment interval. Dialysis disequilibrium syndrome-a syndrome of acute neurologic symptoms and cerebral edema after RRT-is the clinical entity in which the effect of acute osmolality change has been most studied. It has been theorized that rapid serum BUN reduction accompanying RRT creates an osmolar gradient between the brain and serum. Since the brain is not freely permeable to BUN, water flows down the osmolar gradient in to the brain (12, 13) . Uremic animals demonstrate postdialysis urea gradients consistent with observed degrees of cerebral edema (36, 37) . Furthermore, uremic rats experience reduced brain expression of urea transporters and increased aquaporin-4 water channel expression while aquaporin-4 expression also increases during liver failure (38) (39) (40) . These molecular changes facilitate cerebral edema formation in the presence of a urea gradient. The associations seen in our cohort could be due to a similar mechanism of acute osmolar gradient generation, delayed osmolyte equilibration, and facilitated water movement in to the brain.
There are limitations to our study. Retrospective methods limit our ability to account for confounders. Although we assessed for an effect of timing delay between CT and osmolality collection, a prospective investigation with contemporaneous CT and biochemical sample acquisition would be required to eliminate the potential bias of timing delays. The single center design may limit generalizability. Our attention to osmolality likely mitigated the potential for severe osmolality changes that could be observed at centers where osmolality monitoring is not routine. Our preference to avoid ICP monitors prevents us from commenting on associations with ICP (27) . Although our data are consistent with a mechanistic effect of osmolality in both ALF and ACLF, the reader should be aware of additional unique contributors to HE, such as inflammation, and the possibility that the magnitude of effect from specific mechanisms may differ between these groups (2, 6) . Clinical trials based on mechanistic research studies in HE should investigate therapeutic effects in ALF and ACLF separately.
CONCLUSIONS
Acute changes in serum osmolality are independently associated with changes in intracranial CSF volume-a biomarker of brain volume change due to cerebral edema-and neurologic function in patients with severe HE. Measuring serum osmolality in severe HE may be beneficial since a hyperosmolar state may exist despite low or normal serum sodium. Efforts to avoid acute reductions in serum osmolality may minimize cerebral edema and neurologic deterioration in patients with severe HE.
